CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 ...

Today the FDA announced the approval of the gonadotropin-releasing hormone receptor inhibitor degarelix for the treatment of advanced prostate cancer. The injectable drug is the first new drug ...

Longer time to PSA failure is thought to be desirable as it may be indicative of time to castrationresistant prostate cancer (CRPC) and may delay initiation of second-line therapy, which includes ...

Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...

To earn CME related to this news article, click here. January 9, 2009 — The US Food and Drug Administration (FDA) has approved fludarabine phosphate tablets for the treatment of B-cell chronic ...

FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

FIRMAGON (degarelix injection) 80mg and 120mg vials of powder for reconstitution by Ferring Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its ...

THOUSANDS of men suffering from advanced prostate cancer have been thrown a lifeline after a drug that can dramatically slow the progress of the disease has finally been approved following an ...